Dyne Therapeutics’ (DYN) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report released on Wednesday,Benzinga reports. HC Wainwright currently has a $55.00 price objective on the stock.

Several other equities analysts have also issued reports on DYN. Morgan Stanley lifted their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Guggenheim increased their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Finally, Stifel Nicolaus lifted their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, August 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $51.40.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $28.39 on Wednesday. The company has a market cap of $2.89 billion, a P/E ratio of -7.97 and a beta of 1.10. The business’s 50 day moving average price is $32.48 and its 200-day moving average price is $35.17. Dyne Therapeutics has a fifty-two week low of $9.76 and a fifty-two week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, equities analysts predict that Dyne Therapeutics will post -3.02 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In related news, SVP Richard William Scalzo sold 1,390 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the completion of the transaction, the senior vice president now directly owns 98,568 shares of the company’s stock, valued at $3,405,524.40. This represents a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Dirk Kersten sold 23,671 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the transaction, the director now owns 99,652 shares of the company’s stock, valued at $3,522,698.20. This represents a 19.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 158,975 shares of company stock worth $5,693,789 over the last quarter. 20.77% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its position in Dyne Therapeutics by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock worth $66,802,000 after purchasing an additional 84,760 shares during the period. Barclays PLC increased its stake in Dyne Therapeutics by 162.2% in the 3rd quarter. Barclays PLC now owns 207,309 shares of the company’s stock valued at $7,446,000 after purchasing an additional 128,246 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Dyne Therapeutics during the third quarter worth $1,067,000. XTX Topco Ltd purchased a new stake in Dyne Therapeutics during the third quarter worth $573,000. Finally, Sphera Funds Management LTD. purchased a new position in shares of Dyne Therapeutics in the third quarter valued at $2,030,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.